Conference Reports for NATAP

IAS 2023 July 23rd - 26th 12th IAS Conference on HIV Science Back

Lenacapavir at 2023 IAS       The Phase 2 clinical trial (NCT05052996 ) evaluating an investigational oral once-weekly combination treatment regimen of islatravir and Gilead's lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir.   https://www.natap.org/2022/HIV/092022_01.htm   IAS: Participant-Reported Outcomes With Long-Acting Lenacapavir-Based Regimens Among Heavily Treatment-Experienced People Living With HIV in the CAPELLA Clinical Trial - (07/25/23)   IAS: Healthcare provider experience of administering long-acting lenacapavir for people with HIV with heavy treatment experience, engaged through a compassionate use program in the United States - (08/01/23)   IAS: Comparison of Long-Acting Lenacapavir Phase 2/3 Regimen vs Simplified Regimen Using Population-PK Analysis and Simulation - (07/26/23)   IAS: Recommendations for Missed Oral Lenacapavir Loading Doses Using Population-Pharmacokinetics-Based Simulations - (07/26/23)   IAS: Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/27/23)   IAS: Lenacapavir Oral Bridging (300 mg QW) Maintains Efficacy with a Similar Safety Profile When SC LEN Cannot Be Administered - (07/26/23)   IAS: Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV - (07/25/23)